Malignant salivary gland tumours: treatment outcomes from a tertiary referral centre in the UK

Br J Oral Maxillofac Surg. 2023 May;61(4):295-301. doi: 10.1016/j.bjoms.2023.03.005. Epub 2023 Mar 17.

Abstract

Salivary gland malignant tumours are a complex and highly variable pathological group. Their diagnosis can be challenging, and management is guided by multidisciplinary teams. This project aimed to establish clinicopathological and sociodemographic features that significantly impacted overall disease-free or progression-free survival in patients diagnosed with malignant salivary gland disease between 2010 and 2019 in a tertiary referral centre. In total, 86 patients were included for analysis, with a female:male gender ratio of 1.3:1. Mean age at diagnosis was 57.7 years. Mucoepidermoid carcinomas constituted almost 25% (n = 20) of all cases, with adenoid cystic carcinomas (20%, n = 17) and acinic cell carcinomas (17.5%, n = 15) being the next most frequently diagnosed. The parotid gland was the most frequently affected site (80.2%, n = 69). Perineural and lymphovascular invasion, and a maximum tumour dimension of ≥4 cm were highly associated with the decision to provide a neck dissection as part of treatment. Involved margins, extracapsular spread, and lymphovascular and perineural invasion were associated with the need for adjuvant treatment. However, no factors remained statistically significant on multivariate analysis. This retrospective service evaluation demonstrates the difficulty of predicting treatment outcomes for patients diagnosed with malignant salivary gland disease.

Keywords: Carcinoma; Salivary gland; Survival; Tumour.

MeSH terms

  • Carcinoma, Adenoid Cystic* / therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Salivary Gland Neoplasms* / pathology
  • Salivary Gland Neoplasms* / therapy
  • Tertiary Care Centers
  • Treatment Outcome
  • United Kingdom